Literature DB >> 15218471

Pharmacologic inhibition of nitric oxide synthases and cyclooxygenases enhances intimal hyperplasia in balloon-injured rat carotid arteries.

Jens W Fischer1, Suzanne Hawkins, Alexander W Clowes.   

Abstract

OBJECTIVE: Extensive proliferation and migration of smooth muscle cells (SMCs) contribute to development of fibromuscular intimal hyperplasia in response to balloon catheter-induced injury of the left carotid artery in Fischer 344 rats. The purpose of the present study was to test the hypothesis that endogenously generated nitric oxide (NO) and prostaglandins act synergistically to limit the extent of neointimal hyperplasia.
METHODS: The left carotid artery of Fischer 344 rats was injured with a 2F balloon catheter. The following treatment was initiated 24 hours before arterial injury, and was continued for 2 weeks: N-nitro-l-arginine (L-NA; 10 mg/kg/d, in drinking water), indomethacin (1.5 mg/kg/d per gavage), and L-NA (10 mg/kg/d) plus indomethacin (1.5 mg/kg/d). After application of an overdose of pentobarbital animals were formalin-fixed. Subsequently, paraffin-embedded cross sections of the uninjured and injured carotid arteries were analyzed morphometrically. SMC proliferation was determined by incorporation of 5-bromo-2'-deoxyuridine.
RESULTS: Two weeks after injury, L-NA caused a 1.29-fold +/- 0.29-fold (mean +/- SD; n = 14; P <.05) increase in the intima-media ratio, compared with control animals, whereas indomethacin had no effect. Combined treatment with L-NA plus indomethacin further increased intima-media ratio (1.65-fold +/- 0.5-fold over control; n = 14; P <.05). SMC proliferation in the neointima of rats treated with L-NA and L-NA plus indomethacin was elevated. Furthermore, neointimal cell density (nuclei per square millimeter) was reduced after combined inhibition of cyclooxygenases and NO synthases.
CONCLUSION: The present results of pharmacologic NO synthase and cyclooxygenase inhibition suggest that NO and prostaglandins are part of an endogenous growth inhibitory mechanism that synergistically suppresses intimal thickening. CLINICAL RELEVANCE: The role of cyclooxygenase-1 (COX1) and cyclooxygenase-2 (COX2) during vascular recurrent stenosis and atherosclerosis is not clear yet. In particular, the effects of selective COX2 inhibitors on the frequency of cardiovascular events is still controversial. It is shown here in rats that the application of a non-selective COX inhibitor does not affect arterial stenosis. However, the concurrent inhibition of endogenous nitric oxide generation and COX1 or COX2 causes overshooting neointimal hyperplasia. These results suggest that increased vascular stenosis can result from administration of drugs that pharmacologically block 2 or more inhibitory pathways that normally counterbalance the effect of promotors of neointimal hyperplasia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15218471      PMCID: PMC1381983          DOI: 10.1016/j.jvs.2004.03.037

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  41 in total

1.  Overexpression of inducible nitric oxide synthase by neointimal smooth muscle cells.

Authors:  Z Yan; G K Hansson
Journal:  Circ Res       Date:  1998 Jan 9-23       Impact factor: 17.367

Review 2.  Antimitotic actions of vasodilatory prostaglandins--clinical aspects.

Authors:  H Sinzinger; P Fitscha; H Kritz
Journal:  Agents Actions Suppl       Date:  1997

3.  Overexpression of human endothelial nitric oxide synthase in rat vascular smooth muscle cells and in balloon-injured carotid artery.

Authors:  L Chen; G Daum; R Forough; M Clowes; U Walter; A W Clowes
Journal:  Circ Res       Date:  1998-05-04       Impact factor: 17.367

4.  Human endothelial nitric oxide synthase gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation after balloon injury in rats.

Authors:  S Janssens; D Flaherty; Z Nong; O Varenne; N van Pelt; C Haustermans; P Zoldhelyi; R Gerard; D Collen
Journal:  Circulation       Date:  1998-04-07       Impact factor: 29.690

5.  Nitric oxide modulates basal and endothelin-induced coronary artery vascular smooth muscle cell proliferation and collagen levels.

Authors:  M A Rizvi; P R Myers
Journal:  J Mol Cell Cardiol       Date:  1997-07       Impact factor: 5.000

6.  Perivascular delivery of a nitric oxide donor inhibits neointimal hyperplasia in vein grafts implanted in the arterial circulation.

Authors:  A Chaux; X M Ruan; M C Fishbein; Y Ouyang; S Kaul; J A Pass; J M Matloff
Journal:  J Thorac Cardiovasc Surg       Date:  1998-03       Impact factor: 5.209

7.  Nitric oxide-induced downregulation of Cdk2 activity and cyclin A gene transcription in vascular smooth muscle cells.

Authors:  K Guo; V Andrés; K Walsh
Journal:  Circulation       Date:  1998-05-26       Impact factor: 29.690

8.  The G3 domain of versican enhances cell proliferation via epidermial growth factor-like motifs.

Authors:  Y Zhang; L Cao; B L Yang; B B Yang
Journal:  J Biol Chem       Date:  1998-08-14       Impact factor: 5.157

9.  Efficient inhibition of intimal hyperplasia by adenovirus-mediated inducible nitric oxide synthase gene transfer to rats and pigs in vivo.

Authors:  L L Shears; M R Kibbe; A D Murdock; T R Billiar; A Lizonova; I Kovesdi; S C Watkins; E Tzeng
Journal:  J Am Coll Surg       Date:  1998-09       Impact factor: 6.113

10.  Differential induction of cyclooxygenase-2 in human arterial and venous smooth muscle: role of endogenous prostanoids.

Authors:  D Bishop-Bailey; J R Pepper; S W Larkin; J A Mitchell
Journal:  Arterioscler Thromb Vasc Biol       Date:  1998-10       Impact factor: 8.311

View more
  8 in total

1.  Nitric oxide-loaded echogenic liposomes for nitric oxide delivery and inhibition of intimal hyperplasia.

Authors:  Shao-Ling Huang; Patrick H Kee; Hyunggun Kim; Melanie R Moody; Stephen M Chrzanowski; Robert C Macdonald; David D McPherson
Journal:  J Am Coll Cardiol       Date:  2009-08-11       Impact factor: 24.094

2.  Study of vascular injuries using endothelial denudation model and the therapeutic application of shock wave: a review.

Authors:  Cheuk-Kwan Sun; Pei-Lin Shao; Ching-Jen Wang; Hon-Kan Yip
Journal:  Am J Transl Res       Date:  2011-04-08       Impact factor: 4.060

3.  Nitric Oxide-Enhanced Molecular Imaging of Atheroma using Vascular Cellular Adhesion Molecule 1-Targeted Echogenic Immunoliposomes.

Authors:  Hyunggun Kim; Patrick H Kee; Yonghoon Rim; Melanie R Moody; Melvin E Klegerman; Deborah Vela; Shao-Ling Huang; David D McPherson; Susan T Laing
Journal:  Ultrasound Med Biol       Date:  2015-03-24       Impact factor: 2.998

4.  Inhibition of smooth muscle proliferation by urea-based alkanoic acids via peroxisome proliferator-activated receptor alpha-dependent repression of cyclin D1.

Authors:  Valerie Y Ng; Christophe Morisseau; John R Falck; Bruce D Hammock; Deanna L Kroetz
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-08-17       Impact factor: 8.311

5.  Nitric oxide pretreatment enhances atheroma component highlighting in vivo with intercellular adhesion molecule-1-targeted echogenic liposomes.

Authors:  Patrick H Kee; Hyunggun Kim; Shaoling Huang; Susan T Laing; Melanie R Moody; Deborah Vela; Melvin E Klegerman; David D McPherson
Journal:  Ultrasound Med Biol       Date:  2014-03-05       Impact factor: 2.998

6.  Liposomal modular complexes for simultaneous targeted delivery of bioactive gases and therapeutics.

Authors:  Melvin E Klegerman; Michael Wassler; Shao-Ling Huang; Yuejiao Zou; Hyunggun Kim; Harnath S Shelat; Christy K Holland; Yong-Jian Geng; David D McPherson
Journal:  J Control Release       Date:  2009-11-10       Impact factor: 9.776

7.  Cell selective cardiovascular biology of microsomal prostaglandin E synthase-1.

Authors:  Lihong Chen; Guangrui Yang; Xiufeng Xu; Gregory Grant; John A Lawson; Mohammad Bohlooly-Y; Garret A FitzGerald
Journal:  Circulation       Date:  2012-11-30       Impact factor: 29.690

8.  Cilostazol attenuates intimal hyperplasia in a mouse model of chronic kidney disease.

Authors:  Wiwat Chancharoenthana; Asada Leelahavanichkul; Sujittra Taratummarat; Jutamas Wongphom; Khajohn Tiranathanagul; Somchai Eiam-Ong
Journal:  PLoS One       Date:  2017-12-05       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.